ERBB2 and metastasis: Our finding that when stratifying by HER2-null (IHC0) versus low or greater (IHC ≥ 1 + ), which is the key stratification for T-DXd, one in five patients have discordant HER2 expression in their first brain metastasis compared to their primary breast cancer.